Satellos Q2 2026 loss widens as R&D spending rises on SAT-3247 BASECAMP, TRAILHEAD trials, company says

Reuters2026/08/13 21:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Satellos posted a net loss of USD 11.72 million in Q2 2026, widened from USD 5.61 million as spending rose.
R&D expense climbed to USD 9.64 million from USD 4.44 million, driven by BASECAMP and TRAILHEAD clinical activity.
Higher manufacturing work and preclinical safety studies also lifted R&D costs, alongside increased headcount supporting expanded development.
G&A expense increased to USD 2.53 million from USD 1.93 million, reflecting higher professional fees and operating costs tied to Nasdaq reporting.
Cash and short-term investments totaled USD 61.84 million at June 30, 2026, up from USD 27.71 million following USD 51.9 million net offering proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Satellos Q2 2026 loss widens as R&D spending rises on SAT-3247 BASECAMP, TRAILHEAD trials, company says

You may also like

Crypto prices